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INTRODUCTION
Fibromyalgia (FM) is a poorly understood chronic condition characterized by widespread musculoskeletal pain, fatigue, unrefreshing sleep, memory and attention difficulties, among other symptoms (Clauw, 2014) . While the etiology of FM is unknown, central mechanisms are strongly implicated, including evidence of abnormalities in structure, function, and molecular chemistry of the central nervous system (CNS) (Albrecht et al., 2016; Clauw, 2014; Dehghan et al., 2016; Flodin et al., 2014; Gracely et al., 2002; Harris et al., 2007; Jensen et al., 2009; Jensen et al., 2010; Jensen et al., 2013; Kuchinad et al., 2007; Loggia et al., 2014; Loggia et al., 2015a; Napadow and Harris, 2014; Schreiber et al., 2017; Schrepf et al., 2016; Wood, 2008) , though some evidence points to peripheral alterations as well (Oaklander et al., 2013; Uceyler and Sommer, 2013) .
Dysregulation of neuroimmune activation is one potential mechanism contributing to previously reported central aberrations and central sensitization in FM. For instance, FM patients demonstrate elevated levels of fractalkine and interleukin-8 (IL-8) in cerebrospinal fluid (CSF) (Backryd et al., 2017; Kadetoff et al., 2012; Kosek et al., 2015) . Both chemokines are implicated in neuron-glial communication (Montague and Malcangio, 2017; Puma et al., 2001) , and have been associated with central sensitization and pain (Kosek et al., 2015; Montague and Malcangio, 2017) . However, no study to date has clearly demonstrated that glial activation occurs in the brain of FM patients. Acknowledging a role for neuroimmune dysfunction in FM would open the exploration of glial modulation as a therapeutic option for this condition.
In the human CNS, glial activation can be studied in vivo using positron emission tomography (PET) and radioligands that bind to the 18-kDa translocator protein (TSPO), such as [ 11 C]PBR28, which displays nanomolar affinity to this protein (~0.5nM; Imaizumi et al., 2008) . Located mainly on the outer mitochondrial membrane, TSPO expression is low in healthy CNS tissue, but is widely upregulated in microglia and astrocytes under inflammatory conditions (Lavisse et al., 2012; Rupprecht et al., 2010) . Our group has recently used TSPO PET imaging to document neuroimmune activation in the central and peripheral nervous system of patients with chronic low back pain (CLBP) (Albrecht et al., 2018; Loggia et al., 2015b) . While no TSPO PET studies of FM patients have been published yet, a possible link between TSPO and FM pathophysiology is provided by an association between the Ala147Thr polymorphism (rs6971) in the TSPO gene and FM symptom severity and cerebral pain processing .
The aims of the current study were to evaluate the hypothesis that brain TSPO binding in FM patients, as assessed using the [ 11 C]PBR28 PET ligand, is 1) elevated compared to healthy controls (indicating the presence of glial activation) and 2) correlated with specific symptoms attributable to FM pathophysiology. An additional third aim was to tease out the most likely cellular sources of increased TSPO binding because, while TSPO upregulation in neuroinflammatory responses consistently colocalizes with microglia, an accompanying astrocytic component has been observed in some (Liu et al., 2016; Rupprecht et al., 2010; Toth et al., 2016; Wei et al., 2013) , but not all cases (Abourbeh et al., 2012; Mirzaei et al., 2016) . To this end, a smaller sample of FM patients received a PET scan with [ 11 C]-L-deprenyl-D2, which binds to monoamine oxidase B (MAO-B) with high specificity in postmortem tissue (~30 fmol/mg tissue; Gulyas et al., 2011) . Because the expression of MAO-B in glial cells is thought to be predominantly, if not exclusively, within astrocytes (Ekblom et al., 1994) , we reasoned that the presence of elevations in 
MATERIALS AND METHODS

Study Design
This collaborative project combines data from two independent research centers to , and all subjects provided informed consent. The initial study design and data collection at each site were completed independently, and the decision to aggregate the data into a common analysis was made after completion of data collection. Potential confounds attributable to site-specific differences were taken into account in the statistical models of the combined dataset. Group differences identified in the primary analysis of the combined dataset were also assessed within each site separately. Because arterial plasma data were collected for all subjects scanned at Karolinska, we decided to perform two levels of analyses. The first analysis took advantage of the arterial blood data collected at Karolinska, in order to obtain quantitative distribution volume (VT) metrics using kinetic modeling. The second analysis employed a blood-free ratio approach previously validated in separate cohorts (Albrecht et al., 2017) , and utilized the enhanced statistical power of the combined sample (31 patients vs. 27 controls). An evaluation of the agreement between VT computed in the smaller (KI only) sample and SUVR in the larger, combined sample (KI+MGH) was perfomed by assessing the extent of spatial overlap of the group differences, as well as the regional correlation of these metrics. (Canat et al., 1993; Clow et al., 1985; Gehlert et al., 1985; Kalk et al., 2013; Wamsley et al., 1993 Kreisl et al., 2013a; Owen et al., 2010; Owen et al., 2012) . Sixteen subjects were Ala/Ala (i.e., high-affinity binders;;HABs: FM n=8; HC n=8) and six were Ala/Thr (i.e., mixed-affinity binders; MABs: Beck et al., 1961) , and Pain Catastrophizing Scale (PCS; Sullivan et al., 1995) . All items were completed on the day of the scan, with the exception of the ACR survey for all KI patients and two MGH patients, and the BDI for MGH patients, which were completed only during the screening visit. Because 17 MGH patients completed the ACR survey on both the scan day and during the screening visit, we were able to confirm that this questionnaire has good temporal stability by correlating the scores across visits. All subscales of the ACR survey showed high to moderate intercorrelations (total: r=0.785, p<0.001; symptom severity: r=0.788, p<0.001; widespread pain index: r=0.728, p=0.001; fatigue: r=0.534, p=0.027; trouble thinking: r=0.581, p=0.015; waking up tired: r=0.810, p<0.001) , supporting the temporal stability of these measures, and therefore the appropriateness of evaluating these variables in relation to imaging metrics collected at different timepoints.
Subjects
Prior to tracer injection on the scan day, all patients also rated their pain on a visual analog scale, anchored by 0 ("No pain at all") and 100 ("Most intense pain tolerable"). Prior to PET scanning, subjects received a cubital vein catheter for intravenous radioligand administration and a radial artery catheter in the contralateral arm for arterial blood sampling.
Positron Emission
To minimize motion during the PET data acquisition, each participant wore an individuallydesigned helmet, placed in a frame holder.
Preparation, injection and PET data acquisition for [ 11 C]PBR28 have been described previously Kanegawa et al., 2016 was excluded from the analysis. Arterial blood data pre-processing was performed using Kaleidagraph 4.1 software (Synergy Software) as described previously .
Radioligand metabolism correction was performed using the parent fraction in PMOD v3.3
(pixel-wise modelling software; PMOD Technologies Ltd., Zurich, Switzerland) where individual parent fraction data was fit with a 3-exponential model.
Massachusetts General Hospital. Imaging was performed at the MGH/HST Athinoula
A. Martinos Center for Biomedical Imaging in Charlestown, MA. [ 11 C]PBR28 was produced in-house using a procedure modified from the literature (Imaizumi et al., 2007) .
scans were performed for 90 minutes with an integrated PET/MR scanner consisting of a dedicated brain avalanche photodiode-based PET scanner in the bore of a Siemens 3T Tim
Trio MRI (Kolb et al., 2012 
PET Data Analysis and Quantification
Kinetic analysis. Estimation of [
11 C]PBR28 distribution volume (VT) was performed using Logan graphical analysis with a metabolite corrected plasma input function (Logan et al., 1990) , based on five frames from 33 to 63 minutes. For each PET scan, a parametric VT image was generated using the stationary wavelet aided parametric imaging (WAPI) approach (Cselenyi et al., 2002) . WAPI analysis of TSPO binding has been previously shown to be sensitive to within-subject changes in VT Jucaite et al., 2015) , and has shown both high correlation with VT estimated with the two-tissue compartment model (2TCM), and good reliability for 63 minutes of data .
]-L-deprenyl-D2 data was performed as described previously, utilizing the 2TCM with three rate constants (K1, k2, k3) with PMOD 3.3 (Sturm et al., 2017) .
The outcome measure λk3 was calculated as (K1/k2)*k3 which has been shown to reflect the regional enzyme concentration more accurately than k3 alone (Fowler et al., 1995; Logan et al., 2000) . There is presently no validated method to produce λk3 parametric images with the images, normalized to MNI standard space, and spatially smoothed with an 8mm FWHM Gaussian kernel, as in Loggia et al., (2015b) and Albrecht et al., (2017) .
Statistical analysis
Differences in continuous variables were assessed by performing a GLM analysis with Group and Site as fixed factors, and a Group*Site interaction term. Significant interaction terms were decomposed with post-hoc planned comparisons of least squares means. Differences in the distribution of categorical variables were assessed with Chi-Square tests. Between-site differences in FM questionnaire scores were assessed with two-sample ttests.
As the primary analysis, voxelwise group comparisons of [ For follow up analyses and illustration purposes, clusters of significant group differences from the SUVR or VT analysis (Figs 1-3) were parcellated into separate anatomically-constrained subregions, using the labels from the Harvard-Oxford probabilistic atlas (using an arbitrary threshold of 30). Average SUVR and/or VT values were extracted from these regions, for the purposes of visualizing data, comparing group effects within each site independently, and assessing relationships between SUVR and clinical variables and between outcome metrics (SUVR and VT). Although anterior middle cingulate (aMCC) did not exhibit significant group differences in the voxelwise VT analysis, this region was significant in the SUVR analysis (see Results); therefore, average VT was extracted from aMCC to test for potential VT differences not detected in the voxelwise analysis, particularly because this region is highly relevant to pain processing (Kragel et al., 2018; Shackman et al., 2011) . Partial correlation analyses were used to assess correlations between PET signal extracted from regions exhibiting significant group differences in the voxelwise analyses and continuous clinical variables (i.e. ACR [total score, symptom severity score, widespread pain index], FIQR, BDI, PCS, and current VAS pain), correcting for TSPO polymorphism. These analyses were performed using SUVR, as these values were available for all patients at both sites. To assess the relationship between extracted PET signal and ordinal clinical variables (individual ACR symptom severity items: "fatigue", "trouble thinking or remembering", "waking up tired"), we performed GLM analyses with TSPO PET signal as the dependent variable, clinical score as a fixed factor ("slight or mild problem", "moderate problem", or "severe problem"), and TSPO polymorphism and study site as regressors of no interest. Posthoc planned comparisons of least squares means were performed to decompose significant main effects. Additionally, partial correlation analysis was used to evaluate the association between [ 11 C]PBR28 VT and SUVR in participants for whom both measures were available, correcting for TSPO polymorphism.
After identifying regions demonstrating group differences in the combined [ 11 C]PBR28 SUVR datasets, we conducted a follow up GLM analysis of the data extracted from the same regions, in order to evaluate the significance of the Site effect and the Group*Site interaction, using TSPO genotype and injected dose as regressors of no interest, and to compute the effect size, using Cohen's d, for each site independently. The primary aim of these analyses was to assess whether the group differences identified in the voxelwise analyses were driven solely by one site, or could rather be similarly observed at both sites. In order to avoid circularity, we do not report the p-values for the Group effects at each site independently, as these analyses were performed on data extracted from regions preselected because they already exhibited a Group effect in the voxelwise analyses.
For all demographic, correlation, and follow-up analyses, significance was set as p<0.05, uncorrected.
Unpaired t-tests were used to assess group differences in [ 11 C]-L-deprenyl-D2 λk3 for each region with elevated TSPO signal, which included: aMCC, dLPFC, dmPFC, frontoinsular cortex, S1/M1, PCC, precuneus, pMCC, SMA, and SPL (see Results). Unpaired t-tests were also performed for the exploratory analysis of 23 anatomically define ROIs, and whole brain and gray matter. However, because no group differences were significant in any ROI, all analyses were followed up by exploratory uncorrected analyses to provide more convincing support to the claim that the lack of group effects reported in the deprenyl analyses are likely to reflect the lack of astrocytic activation in FM.
Please refer to Supplementary Table 2 for a summary of the statistical analyses.
RESULTS
Subject characteristics
Demographic and other key characteristics for all subjects are shown in (Fig. 1) , including dorsolateral prefrontal cortex (dlPFC), dorsomedial PFC (dmPFC), primary somatosensory and motor cortices (S1/M1), precuneus, posterior cingulate cortex (PCC), supplementary motor area (SMA), supramarginal gyrus (SMG), and superior parietal lobule (SPL).
Additionally, an ROI analysis of the aMCC revealed elevated VT in the FM patients that approached statistical significance (p=0.071). There were no regions where control VT was significantly higher than FM VT.
[ 11 C]PBR28 SUVR comparison (KI + MGH). A whole brain voxelwise analysis
identified several brain regions where SUVR in FM patients was significantly greater than in HC (Fig. 2) . These regions largely overlapped those identified in the VT analysis (dlPFC, dmPFC, S1/M1, precuneus, PCC, SMA, SPL) but also revealed effects in additional regions (aMCC, posterior MCC [pMCC], and frontoinsular cortex). There were no regions where SUVR was significantly higher in healthy controls relative to FM patients. Supplementary voxelwise analyses, including specific activity and injected mass as regressors of no interest, showed similar outcomes to the primary analysis, which included injected dose as a regressor of no interest ( Supplementary Fig 1) .
Following these voxelwise analyses, we performed a post-hoc regional analysis of the areas demonstrating SUVR group differences, in order to evaluate whether the effects emerging in the combined dataset could be similarly observed at each site independently ( (Table 4 ; Fig. 2 ), indicating medium or large effect size for all examined regions at both sites (Cohen, 1988) , although the magnitude of the difference was generally larger for the KI study.
[ 11 C]PBR28 analysis: Agreement between SUVR and VT (KI sample only). The regions identified in the voxelwise SUVR analysis displayed a large degree of spatial overlap with
results from the VT analysis. To visualize this, we created an image showing common regions identified in both analyses as significantly higher in FM patients. These regions included dlPFC, dmPFC, PCC, precuneus, S1/M1, SMA, and SPL (Fig. 3, left) . In addition to this spatial agreement across analyses, we were able to evaluate the association across metrics in the KI participants, for whom both SUVR and VT were available. Statistically significant positive correlations were observed for S1/M1 (r=0.453, p=0.039; Fig. 3 
[ 11 C]PBR28 analysis: Association with clinical variables (KI + MGH)
Within FM patients, an exploratory GLM analysis revealed that the scores of the Figure 2) .
[ 11 C]-L -deprenyl-D 2 analysis: Group differences (KI sample only)
DISCUSSION
The current study provides evidence of elevated TSPO binding, as measured with
in patients with fibromyalgia (FM) compared to healthy controls (HC).
This marker of glial activation was increased in several brain regions implicated in FM pathology from previous neuroimaging studies. We also report positive associations between TSPO PET signal in several of these regions and subjective ratings of fatigue, one of the most common symptoms reported by FM patients (Clauw, 2014; Wolfe et al., 2011) . Our observations are supportive of a role for neuroimmune/glial activation in FM pathology.
These results conform to a body of clinical data suggesting a possible association between neuroinflammation and FM. Several studies of FM patients demonstrated elevated CSF levels of molecules implicated in neuroglial signaling, such as fractalkine and IL-8 (Backryd et al., 2017; Kadetoff et al., 2012; Kosek et al., 2015) . Furthermore, previous studies showed increased endogenous opioidergic tone in FM (Schrepf et al., 2016) , which could be of relevance as opioid-induced hyperalgesia is associated with glial activation (Roeckel et al., 2016) . In line with this evidence, some pharmacological treatments involving the opioid system and/or with putative inhibitory actions on glial cells are beneficial for FM.
One example of this is low-dose naltrexone, an opioid antagonist, which is proposed to inhibit glial activation (Mattioli et al., 2010) and has been shown to have beneficial effects in FM (Younger and Mackey, 2009; . Additionally, serotonin/noradrenaline reuptake inhibitors (SNRIs; e.g., duloxetine, milnacipran, etc.) are among the most commonly prescribed pharmacological treatments for FM, and show moderate effectiveness in reducing some FM symptoms (Welsch et al., 2018) . While the primary mechanism of action of SNRIs is to normalize concentrations of endogenous monoamine neurotransmitters, which are thought to be imbalanced in FM (Albrecht et al., 2016; Kosek et al., 2016; Russell et al., 1992; Wood, 2008) , one potential additional mechanism may be glial modulation, as both duloxetine (Yamashita et al., 2016) and milnacipran (Shadfar et al., 2018) attenuate microglial activation in animal models.
Interestingly, among the regions demonstrating neuroimmune activation in our current study were the PCC/precuneus, a core region of the default mode network, where post-treatment changes in pain related activation were specifically related to the degree of positive clinical response to milnacipran treatment in fibromyalgia patients (Jensen et al., 2014) . Further studies are needed to better understand the specific cellular and molecular mechanisms of FM pharmacotherapies, and the potential role glial cell inhibition plays in their effectiveness.
The utility of TSPO as a marker of glial activation is supported by numerous preclinical and post-mortem studies. While TSPO is ubiquitously expressed by many cell types, it can be used as a sensitive marker of glial activation in vitro because it is dramatically upregulated in glial cells in the context of a neuroinflammatory response. TSPO upregulation has been colocalized with activated microglia and/or astrocytes across a spectrum of CNS disorders, including animal models of neuropathic pain (Liu et al., 2016; Wei et al., 2013) , both animal MS models and human MS lesions (Abourbeh et al., 2012; Chen and Guilarte, 2006; Cosenza-Nashat et al., 2009) , and both animal models of Sclerosis (Datta et al., 2017; Herranz et al., 2016) , in amyloid positive regions in Alzheimer's Disease (Kreisl et al., 2013b; Parbo et al., 2017) , and in the basal ganglia in Huntington's Disease (Lois et al., 2018) . However, while a plethora of human and preclinical studies support TSPO as a glial marker, it is important to note that not all studies have detected TSPO upregulation in neuropathologies with a hypothesized inflammatory component. For instance, previous work showed no differences in TSPO PET signal in cocaine dependence (Narendran et al., 2014) , and decreased signal in alcohol dependence (Hillmer et al., 2017; Kalk et al., 2017) . In patients with psychosis, initial studies with first generation TSPO tracers showed an increase, whereas recent studies using second-generation radioligands are supportive of a decrease in TSPO levels (Plaven-Sigray et al., 2018) . Thus, further work is needed to better assess the potential usefulness of TSPO as a means to image neuroinflammation, and the meaning of the observed TSPO signal changes, particularly in certain pathologies.
In addition, even in conditions for which TSPO may be more established as a marker of glial activation, the specific functional significance of its upregulation remains unclear, and represents an active area of investigation. Numerous preclinical studies show analgesic and anti-inflammatory effects of TSPO agonism, such as increased expression of antiinflammatory IL-10 and other M2-related microglial genes, indicating that changes in TSPO expression might be an adaptive response to a homeostatic challenge (Bae et al., 2014; Liu et al., 2016; Wei et al., 2013) . Similarly, recent in vitro human studies suggest that immune challenges induce TSPO upregulation in anti-inflammatory M2-like macrophages, and TSPO reduction in inflammatory M1-like macrophages Owen et al., 2017) .
We previously documented significantly higher CSF concentrations of IL-10 and other antiinflammatory cytokines in FM patients, as opposed to a more classical (M1-like) proinflammatory CSF cytokine profile in patients with rheumatoid arthritis (RA; Kosek et al., 2015; Lampa et al., 2012) . Altogether, these observations suggest that the [ 11 C]PBR28 PET signal increases in FM patients might be reflective of a M2-like glial phenotype, although in the absence of PET tracers with a higher degree of phenotype specificity this remains speculative.
As mentioned above, elevated TSPO during a neuroinflammatory response may colocalize with both microglia and astrocytes, depending on the specific circumstances. As such, the exact cellular contributions of these glial subtypes to the TSPO PET signal are uncertain. In order to disambiguate the celluar specificity of the TSPO elevations observed in this study, a smaller sample of FM patients, partially overlapping with the sample scanned with [ 11 C]PBR28, was evaluated with [ 11 C]-L-deprenyl-D2, to quantify brain levels MAO-B.
The expression of this protein in glial cells is thought to be predominantly, if not exclusively, within astrocytes, with little to no contribution from monocytes or microglia (Ekblom et al., 1994) . For instance, MAO-B upregulation was found to be colocalized with reactive astrocytes in post-mortem tissues from patients with AD (Nakamura et al., 1990) and ALS (Ekblom et al., 1993; Ekblom et al., 1994) , conditions that also demonstrate elevations in (Johansson et al., 2007; Scholl et al., 2015) . Because in the current study we observed no group differences in [ 11 C]-L-deprenyl-D2 binding, our data suggest that elevated [ 11 C]PBR28 signal in FM patients might be driven by activated microglia rather than astrocytes. Furthermore, the lack of group differences in [ 11 C]-Ldeprenyl-D2 signal in any of the other anatomically-defined brain regions, including whole brain and whole gray matter, suggests that astrocyte activation may not be relevant to the FM pathophysiology.
In line with our current findings of elevated TSPO PET signal in FM patients, we have previously reported brain TSPO elevations in patients with another pain condition, chronic low back pain (Loggia et al., 2015b) . In the cLBP study, we observed a different spatial pattern of glial activation that was localized to the thalamus and areas of the somatosensory and motor cortices consistent with the somatotopic representation of the back and leg, regions in which those participants experienced pain. In the FM patients, by contrast, we observed a pattern which was more spatially extendend, and involved only cortical areas.
The larger cortical spread of neuroinflammation in FM patients compared to cLBP patients might be reflective of the differences in clinical presentation of these two patient groups, as the former report more widespread pain, and a higher incidence of cognitive issues and affective comorbidities (Clauw, 2014) . Of note, the majority of FM patients also report low back pain but, unlike in our previous [ 11 C]PBR28 cLBP study, we did not observe statistically significant elevations in thalamic TSPO PET signal in FM, suggesting that similar pain symptoms in the two disorders may be mediated by distinct mechanisms. On the other hand, TSPO PET signal in the cingulate cortex, which in our FM patients was associated with fatigue scores, was also found to be elevated in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME; Nakatomi et al., 2014) , suggesting glial activation in this region as a potential mechanism underlying pathological fatigue across different conditions. Importantly, our results showed that elevated [ 11 C]PBR28 signal in FM, which was initially identified in the main analysis combining datasets from two different sites (KI+MGH), could be observed within each site separately in follow-up analyses (Fig. 2) . The reproducibility of the effects across sites strengthens confidence in the solidity of our observations. However, we also noticed that the effect sizes for the KI dataset were overall larger compared to those for the MGH dataset. This difference in magnitude of group differences between sites could be a result of several contributing factors, including differences in imaging procedures, e.g., different PET scanners, attenuation correction methodology, tracer injection parameters, tracer synthesis, etc. Additionally, patients from the KI site had significantly higher scores on several ACR items, including symptom severity and trouble thinking clearly (Table 2) , and were less medicated (Table 3) .
Finally, we observed an overlap in the spatial pattern of [ 11 C]PBR28 PET group differences between the SUVR and VT analyses (Fig. 3) , indicating that these analytical techniques may have similar abilities to detect regions exhibiting neuroinflammation in FM.
This observation is in accordance with previous studies comparing [ 11 C]PBR28 metrics computed with (e.g., VT, DVR) or without (e.g., SUVR) an arterial input function in different populations (Albrecht et al., 2017; Lyoo et al., 2015) . While in the current study we also observed significant positive correlations between SUVR and VT in several cortical regions, it should be noted that an association between these metrics has not been consistently observed in the literature (Matheson et al., 2017) . A more thorough investigation of the relationship between SUVR and VT is warranted to better understand this discrepancy across studies.
There are several caveats to take into consideration when interpreting results of the current study. In our voxelwise analyses, we implemented a cluster-forming threshold of z > 2.3, which has been criticized by some for being susceptible to false positives (Eklund et al., 2016 analysis should also be interpreted with caution. Importantly, the absence of a significant effect cannot be used as conclusive proof of no difference, especially with a small sample size as in the current study. Further analysis with larger samples will be thus needed to confirm that astrocytes do not have a key role in the pathophysiology of FM.
In conclusion, our work shows that brain levels of the glial marker, TSPO, as measured using A: Surface projection maps displaying areas with significantly elevated [ 11 C]PBR28 VT in FM patients compared to controls (FM -n=11; HC -n=11) in voxelwise analyses (KI-only sample). B: average ± standard deviation VT extracted from several regions. The S1/M1, dLPFC and precuneus data were extracted from the clusters identified as statistically significant in the voxelwise VT analysis. For these regions, the plots are displayed for illustrative purposes only, and the level of statistical significance noted for each plot reflects that of the voxelwise analyses. For the aMCC, the data was extracted from a region, independently identified based on the results of the SUVR voxelwise analysis (see Fig. 2 ).
The level of statistical significance noted for this region reflects the result of a region-ofinterest analysis.
SPL -superior parietal lobule, S1 -primary somatosensory cortex, M1 -primary motor cortex, SMG -supramarginal gyrus, dlPFC -dorsolateral prefrontal cortex, SMAsupplementary motor area, PCC -posterior cingulate cortex, dmPFC -dorsomedial prefrontal cortex. The barplots for S1/M1, dlPFC and Precuneus are for illustrative purposes.
The barplot for aMCC illustrates an ROI analysis (p=0.071) Four representative regions showing significant group differences in the [ 11 C]PBR28 SUVR analysis (Fig 2) show no differences in [ 11 C]-L-deprenyl-D2 λk3 (p≥0.53 uncorrected).
Surface projections of individual regions are displayed in red above the plots. 
